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Colorectal carcinogenesis involves environmental factors and genetic predispositions.  Re-
cent studies have suggested the associations between colorectal neoplasm and functional 
polymorphism of matrix metalloproteinases (MMPs) and cytokine genes.  In this study, we 
analyzed polymorphisms of MMPs and tumor necrosis factor (TNF)-alpha genes, focusing 
on the susceptibility to colorectal neoplasm and the tumor progression.  The subjects were 
186 patients (95 men and 91 women) who underwent total colonoscopy, and were classified 
into cancer, adenoma and non-neoplasm (control) groups of 47, 72 and 67 patients, respec-
tively.  The polymorphisms at the MMP-2 –1306C/T, MMP-3 –1171 5A/6A, MMP-7 –181A/
G, MMP-9 –1562C/T and TNF-alpha –308G/A loci were analyzed.  Regarding background 
factors, significant differences were found in the age, sex ratio and alcohol-drinking and 
cigarette-smoking histories in the adenoma and cancer groups, compared to those in the 
control group.  On these factors-adjusted logistic regression analysis of polymorphisms 
and disease susceptibility, no significant difference was noted in the frequency of any poly-
morphism in the adenoma and cancer groups, compared to those in the control group. 
The analysis of the involvement of polymorphisms in tumor progression in the adenoma 
and cancer groups revealed that the odds ratio for the MMP-3 5A allele was significantly 
higher in the cancer group (2.74; 95% confidence interval = 1.11–6.74, P = 0.02).  The poly-
morphisms of MMP genes and TNF-alpha genes were not associated with the susceptibil-
ity to colorectal neoplasm, but the involvement of the MMP-3 5A allele in the progression 
of adenoma to cancer was suggested. 
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Recently, the rate of colorectal cancer has been 
increasing rapidly in Japan, and it is now the 
main cause of death from malignant disease, as in 
many other countries (Yoshimi and Sobue, 2004). 
In fact, age-standardized rates are similar to those 
in Caucasian populations of the United States 
(Yiu et al., 2004).  The reason has generally been 
ascribed to the Westernized diet, characterized by 
a high intake of fat and meat, popular after World 
War II (Kono, 2004), whereas the relevance of 
genetic predispositions has not been sufficiently 
analyzed in Japanese.  Colorectal neoplasm is 
known to be a multifactorial disease, with dietary 
factors, lifestyle habits and genetic predispositions 
contributing to its development. 
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 Matrix metalloproteinases (MMPs) are pro-
teolytic enzymes that play key roles not only in 
extracellular matrix degradation but also in all 
stages of cancer initiation, invasion and metasta-
sis (Curran and Murray, 1999; Zhu et al., 2001; 
Behrens et al., 2003).  Furthermore, recent studies 
have suggested that MMPs are involved in tumor 
initiation and development, including the regula-
tion of cell proliferation, apoptosis, angiogenesis, 
loss of cell adhesion and immune responses to 
cancer (Egeblad and Werb, 2002).  In fact, the 
over-expression of MMPs has been demonstrated 
in various cancers (Adachi et al., 1999; Ohashi 
et al., 2000; Aglund et al., 2004; Jordan et al., 
2004).  Polymorphisms of MMPs in the promoter 
region, naturally occurring sequence variations, 
may result in the differential expression of MMPs 
in individuals (Ye, 2000).  To date, the promoters 
of MMP-2, -3, -7 and -9 genes have been reported 
to contain polymorphisms, exhibit allele-specific 
effects on the regulation of MMP gene transcrip-
tion, and have been associated with changes in the 
susceptibility to or development of some cancers 
(Liang et al., 2002; Ghilardi et al., 2002, 2003; 
Matsumura et al., 2005).
 On the other hand, previous studies have 
shown that tumor necrosis factor (TNF)-alpha 
expression may act as a high-risk factor or a poor 
prognostic factor in some cancers (Warzocha et 
al., 1997; El-Omar et al., 2003; Machado et al., 
2003; Sharma et al., 2008).  However, a few previ-
ous reports have suggested that there is no signifi-
cant association between the TNF-alpha –308A/G 
polymorphism allele and colorectal cancer devel-
opment (Park et al., 1998; Landi et al., 2003). 
 To explore the possible association between 
these polymorphisms and the risk of colorectal 
neoplasms, we analyzed promoter genes in MMP-
2, -3, -7 and -9 and TNF-alpha in a Japanese sam-
ple of colorectal neoplasm patients and controls 
who had no finding of colonoscopy.
 
Materials and Methods
 
Subjects
 
A total of 186 Japanese subjects (91 women and 
95 men, with a mean age of 64 ± 13 years) were 
studied between August 2003 and March 2007. 
All subjects had undergone total colonoscopy 
just prior to enrollment.  One hundred nineteen 
patients with histologically confirmed colorectal 
neoplasm (47 cancers and 72 adenomas) and 67 
non-neoplasm subjects (controls) were interviewed 
regarding their medical history, family history of 
colorectal cancer, anamnesis of diabetes, and hab-
its such as alcohol intake and cigarette smoking. 
Before enrollment and blood sampling, written 
informed consent was obtained from all recruited 
subjects.  This study was approved by the Ethics 
Committee of Tottori University Faculty of Medi-
cine.
 
Table 1.  Sequences of PCR primers 
Gene Polymorphism Forward primer and reverse primer (5´–3´) Tm Restriction
   (˚C) enzyme
MMP-2 –1306 C/T CTT CCT AGG CTG GTC CTT ACT GA 60 Xsp I
   CTG AGA CCT GAA GAG CTA AAG AGC T
MMP-3 –1171 5A/6A CTT CCT GGA ATT CAC ATC ACT GCC ACC ACT 65 Tth111 I
   GGT TCT CCA TTC CTT TGA TGG GGG GAA AGA
MMP-7 –181 A/G TGG TAC CAT AAT GTC CTG AAT GAT ACC TAT G 65 EcoR I
   TCG TTA TTG GCA GGA AGC ACA CAA TGA ATT
MMP-9 –1562 C/T GCC TGG CAC ATA GTA GGC CC 60 Sph I
   CTT CCT AGC CAG CCG GCA TC 
TNF-alpha –308 G/A GAG GCA ATA GGT TTT GAG GGC CAT 55 Nco I
   GGG ACA CAC AAG CAT CAA G
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DNA extraction
 
Genomic DNA samples were extracted from pe-
ripheral white blood cells using a DNA extracting 
kit (DnaQuickII: Dainipponseiyaku, Osaka, Ja-
pan) according to the manufacturer’s instructions.
 
 
Determination of genotypes
 
Using the extracted DNA as a template, the pro-
moter region of each MMP was amplified by PCR 
using commercially available kits (HotStarTaq: 
QIAGEN, GmbH, Germany), following the manu-
facturer’s instructions.  The sequences of primers 
are summarized in Table 1.  The methods used 
to type the MMP-2 –1306 C/T, MMP-3 –1171 
5A/6A, MMP-7 –181A/G, MMP-9 –1562 C/T and 
TNF-alpha –308 G/A polymorphisms have been 
described previously (Jormsjö et al., 2001; Vasku 
et al., 2004; Zhang et al., 2004; Perri et al., 2005; 
Tuet al., 2007).  Briefly, reactions were carried out 
under the following conditions:  5 min at 95˚C, 
and then amplification for 35 cycles consisting of 
30 s at 95˚C, 30 s at an appropriate temperature 
and 30 s at 72˚C.  A final extension step at 72˚C 
for 5 to 10 min was added to terminate the am-
plification.  Subsequently, the PCR products were 
digested with appropriate restriction enzymes that 
cleave from 1 to 2 fragments.  The digests were 
then electrophoresed on a 1 to 2% agarose gel us-
ing TBE buffer (45 mM Tris-borate, pH 8.3, and 
2 mM EDTA) to confirm cleavage using molecu-
lar size marker IV (Nippon Gene, Tokyo, Japan). 
Gels were stained with ethidium bromide and 
visualized under UV light. As examples for gel 
documentation, the results of MMPs genotyping 
were shown in Fig. 1. 
Fig. 1.  Genotyping of MMP-2 C/T, MMP-3 5A/6A, MMP-7 A/G and MMP-9 C/T by PCR-restriction fragment 
length polymorphism.  
A: MMP-2 C/T.  The PCR products were digested with XspI restriction enzyme and subjected to electrophoresis on a 2.5% 
agarose gel.  M, molecular marker; 1 and 2, C/T genotype; 3, 4 and 5, C/C genotype.
B: MMP-3 5A/6A.  The PCR products were digested with Tth111I restriction enzyme and subjected to electrophoresis 
on a 2.5% agarose gel.  M, molecular marker; 1, 3 and 4, 6A/6A genotype; 2, 5A/5A genotype; 5, 5A/6A genotype.
C: MMP-7 A/G.  The PCR products were digested with EcoRI restriction enzyme and subjected to electrophoresis on a 
2.5% agarose gel.  M, molecular marker; 1, 2 and 4, A/A genotype; 3 and 5, A/G genotype.
D: MMP-9 C/T.  The PCR products were digested with Sph I restriction enzyme and subjected to electrophoresis on a 
2.5% agarose gel.  M, molecular marker; 1 and 4, C/C genotype; 2 and 3, C/T genotype; 5, C/T genotype.
MMP-2 (–1306 C/T):  Xsp I
MMP-7 (–181 A/G):  ExoR I
MMP-3 (–1171 5A/6A):  Tth111 I
MMP-9 (–1562 C/T):  Sph I
M 1 2 3 4 5
M 1 2 3 4 5
M 1 2 3 4 5
M 1 2 3 4 5
C/T C/C
A/A A/G
6A/6A 5A/5G 5A/6A
C/C C/T T/T
— 193
— 162
194 —
118 —
— 150
— 120
— 435
— 247
— 188
603 —
310 —
234 —
194 —
— 129
— 97
194 —
118 —
(bp) (bp)
A
C
B
D
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Statistical analysis
 
The significance of differences in means or propor-
tions was measured using analysis of variance or 
the chi-square test.  Comparison of the genotypes of 
MMP-2, -3, -7 and -9 and TNF-alpha and the allelo-
type distribution in the study groups was performed 
by means of a 2-sided contingency table using the 
chi-square test.   Relationships between the geno-
types and clinicopathological characteristics of the 
patients were evaluated by Fisher’s exact test.  To 
evaluate the increased risk of colorectal neoplasm 
associated with the presence of polymorphic al-
leles, odds ratios and 95% confidence intervals were 
computed, adjusted by logistic regression for several 
covariates potentially associated with the colorectal 
neoplastic risk such as age, sex, family history of 
colorectal cancer, alcohol intake, smoking status 
and diabetes mellitus.  All statistical analyses were 
performed using the software package SPSS II for 
Windows (version 11.0 J, SPSS Japan, Tokyo)
 
 
Results
 
 
Characteristics of subjects
 
Subjects who had undergone colonoscopy were 
divided into a control group with no finding and 
patient groups with adenoma or cancer of the 
colon.  The backgrounds of groups are shown 
in Table 2.  The mean age was 67.3 ± 1.7 years 
(range: 27–90) in the colorectal cancer group and 
66.3 ± 1.1 years (range: 36–88) in the adenoma 
group.  Compared to the control group, significant 
differences were noted in the age, sex ratio and 
alcohol-drinking history in the adenoma and can-
cer groups.  No significant difference was noted 
in the cigarette-smoking history between the ad-
enoma and control groups (P = 0.10), but one was 
present between the cancer and control groups (P 
= 0.01).  There were no significant differences in 
the familial medical history of colorectal cancer 
or anamnesis of diabetes, compared to the control 
group.
 On comparison of the adenoma and cancer 
groups, no significant differences were present in 
the age, sex ratio, or alcohol-drinking or cigarette-
smoking history, but the frequency of familial 
medical history of colorectal cancer was signifi-
cantly higher in the cancer group (P = 0.007). 
The frequency of anamnesis of diabetes was 
slightly higher in the cancer group, but the differ-
ence was not significant (P = 0.08). 
 
 
Genotype distributions and the suscepti-
bility for adenoma and cancer
 
The frequencies and odds ratios of polymor-
phisms of the MMP-2, -3, -7 and -9 and TNF-
Table 2.  Characteristics of subjects
 Control [67] Patient with
 Ratio Adenoma [72] Cancer [47] 
  Ratio  P† Ratio P†  P‡
Age (year)  61.3 ± 2.0 66.3 ± 1.1 0.04 67.3 ± 1.7 0.04  NS
Sex    Male/female 25/42 42/30 0.02 28/19 0.03  NS
Family history§     Yes/no  8/59  3/69  NS 10/37  NS 0.008
Smoking status     Smoker/non-smoker 19/48 31/41  NS 26/21 0.006  NS
Alcohol status     Drinker/non-drinker 21/46 36/36 0.03 25/22 0.03  NS
Diabetes     Yes/no  5/62  5/67  NS  9/38  NS  NS
 [  ], number of subjects.  
 Ratio, except age (mean ± SD).
 NS, not significant. 
† Compared with the control subjects.
‡ Compared with patients with adenoma.
§ Patients with family history of colorectal cancer in the 1st degree relatives.
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alpha gene are shown in Table 3.  Regarding the 
distribution of alleles in our study, most patients 
had C/C alleles in MMP-2, 6A/6A in MMP-3, A/
A in MMP-7, C/C in MMP-9 and G/G in TNF-
alpha, and, in reverse, none had G/G alleles in 
MMP-7, nor A/A alleles in TNF-alpha.
 Logistic regression analysis adjusted for age, 
sex ratio, and alcohol-drinking and cigarette-
smoking histories, which were background factors 
with significant differences, was performed in the 
control, adenoma and cancer groups. 
 There were no significant differences of 
these genotypes between controls and adenoma 
patients, and between controls and cancer patients, 
suggesting that colorectal neoplasm susceptibility 
was not found in any polymorphism of the MMP-
2, -3, -7 and -9 or TNF-alpha gene. 
Table 3.  Genotype and allele frequencies of polymorphisms of the MMP-2, -3, -7 and -9 and TNF-
alpha gene in controls and patients
     Genotype  Control [67] Patient with adenoma [72] Patient with cancer [47]
     and allele Number Number   Odds ratio† P Number    Odds ratio†   P
 (%)    (%) (95% CI)  (%) (95% CI)
MMP-2 –1306 C/T
     CC 64 (95) 66 (92) 1  41 (87) 1
     CT 3 ( 5) 6 ( 8)   5 (11)
     TT 0 ( 0) 0 ( 0)   1 ( 2)
     CT + TT 3 ( 5) 6 ( 8) 2.39 0.26 6 (13) 2.98 0.17
      (0.51–11.7)     (0.62–14.29)
     T 0.02  0.04    0.07
MMP-3 –1171 5A/6A
     6A6A 50 (75) 58  (81) 1  31 (66) 1
     6A5A 17 (25) 13 (18)   14 (30)
     5A5A 0 ( 0) 1 ( 1)   2 ( 4)
     6A5A + 5A5A 17 (25) 14 (19) 0.79 0.59 16 (34) 1.56 0.32
      (0.34–1.84)     (0.64–3.81)
     5A 0.13  0.1    0.19 
MMP-7 –181 A/G
     AA 55 (82) 65 (90) 1  45 (96) 1
     AG 12 (18) 7 (10)   2 ( 4)
     GG 0 ( 0) 0 ( 0)   0 ( 0)
     AG + GG 12 (18) 7 (10) 0.61 0.35 2 ( 4) 0.21 0.06
      (0.21–1.75)     (0.40–1.11)
     G 0.09  0.05    0.02
MMP-9 –1562 C/T
     CC 47 (70) 54 (75) 1  30 (64) 1
     CT 19 (28) 17 (24)   16 (34)
     TT 1 ( 2) 1 ( 1)   1 ( 2)
     CT + TT 20 (30) 18 (25) 0.78 0.53 17 (36) 1.41 0.41
      (0.35–1.71)     (0.61–3.28)
     T 0.16  0.19    0.13
TNF-alpha –308 G/A 1
     GG 65 (97) 71 (99) 1  46 (98) 1
     GA 2 ( 3) 1 ( 1)   1 ( 2)
     AA 0 ( 0) 0 ( 0)   0 ( 0)
     GA + AA 2 ( 3) 1 ( 1) 0.62 0.71 1 ( 2) 0.77 0.83
      (0.04–8.02)     (0.06–9.31)
     A 0.01  0.01    0.01
 [  ], number of subjects.
 CI, confidence interval.
† Odds ratio adjusted on age, sex, smoking and alcohol status.
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Table 4.  Genotype and allele frequencies of poly-
morphisms of the MMP-2, -3, -7 and -9 and TNF-
alpha gene in patients with adenoma and cancer
   Genotype    Patient with  P
        and  Adenoma Cancer
      allele [72] [47]
 Number  Number  Odds ratio† 
 (%) (%) (95% CI)
MMP-2 –1306 C/T
     CC 66 (92) 41 (87) 1
     CT + TT 6 ( 8) 6 (13) 1.54 0.49
      (0.43–5.488)
MMP-3 –1171 5A/6A
     6A6A 58  (81) 31 (66) 1
     6A5A + 5A5A 14 (19) 16 (34) 2.74 0.02
      (1.11–6.74)
MMP-7 –181 A/G
    AA 65 (90) 45 (96) 1
     AG + GG 7 (10) 2 ( 4) 0.58 0.52
      (0.11–3.00)
MMP-9 –1562 C/T
     CC 54 (75) 30 (64) 1
     CT + TT 18 (25) 17 (36) 1.43 0.41
      (0.61–3.37)
TNF-alpha –308 G/A
     GG 71 (99) 46 (98) 1
     GA + AA 1 ( 1) 1 ( 2) 0.58 0.58
      (0.13–36.13)
 CI, confidence interval.  
† Odds ratio adjusted on family history and diabetes.
 
Association with tumor progression
 
To investigate the association with tumor progres-
sion from adenoma to cancer, the frequencies and 
odds ratios of polymorphisms of the MMP-2, -3, 
-7 and -9 and TNF-alpha gene in the adenoma and 
cancer groups were calculated (Table 4).  Logistic 
regression analysis adjusted for a familial history 
of colorectal cancer and anamnesis of diabetes 
was performed.  We found that patients with the 
MMP-3 5A allele had significantly higher odds 
ratio (2.74) of cancer (P = 0.02).  However, other 
genotypes showed no significant difference be-
tween the adenoma and cancer groups.
 
 
Discussion
 
It has been reported that MMPs play an important 
role in various cancer metastases and invasion 
including colorectal cancer (Asano et al., 2007), 
but no consistent finding has been obtained with 
regard to the association of any MMP gene poly-
morphism with colorectal cancer progression. 
Similarly, no association between TNF-alpha and 
colorectal cancer has been identified.  We inves-
tigated polymorphisms of the MMP-2, -3, -7 and 
-9 and TNF-alpha gene and the susceptibility 
to colorectal neoplasm.  In addition, consider-
ing that most colorectal cancer cases develop via 
the adenoma-carcinoma sequence (Fearon and 
Vogelstein, 1990), we studied the association of 
tumor progression with each gene polymorphism.  
MMP-2 expression in colorectal cancer tissue has 
been reported to be correlated with the disease 
stage and prognosis, and considered to play an 
important role in colorectal cancer invasion and 
metastasis (Turpeenniemi-Hujanen, 2005).  In the 
MMP-2 gene, C/T polymorphism is present at 
–1306, and the transcription activity is higher in 
the C than in the T allele (Price et al., 2001).  In 
studies reported by Heittaratchi et al. (2007) and 
Elander et al. (2006), –1306 C/T was not associat-
ed with the sensitivity of colorectal cancer, 5-year 
survival rate or tumor characteristics, whereas Xu 
et al. (2004) reported that the risk of colorectal 
cancer development was higher in CC than in CT 
and TT types, showing that no consistent findings 
have been obtained with regard to the association 
of MMP-2 gene polymorphisms with colorectal 
cancer.  In our study, no association of MMP-2 
gene polymorphisms with the susceptibility to col-
orectal neoplasm or tumor progression was noted.
 In colorectal cancer tissues, MMP-3 is 
mainly expressed in stromal cells (Newell et al., 
1994).  In the MMP-3 gene, 5A/6A polymorphism 
is present at –1171, and the transcription activity 
is higher in the 5A than in the 6A allele (Ye et al., 
1996).  Hinoda et al. (2002) reported that the 6A 
allele with low transcription activity indirectly 
contributed to colorectal cancer development, but 
no other study has supported this finding (Biondi 
et al., 2000; Ghilardi et al., 2001; Xu et al., 2006; 
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Hettiaratchi et al., 2007).  The clinicopathologi-
cal significance of the MMP-3 expression in col-
orectal cancer remains unclear.  No association 
with colorectal neoplasm susceptibility was noted 
in the present study, but the frequency of the 5A 
allele with high transcription activity during the 
progression of adenoma to cancer was high in the 
cancer group.  Sternlicht et al. (1999) investegated 
the MMP-3 in the breast cancer, and reported 
that MMP-3 promoted spontaneous premalignant 
changes and malignant conversion in the mam-
mary glands of transgenic mice.  Furthermore, re-
garding breast cancer, Nelson et al. (2008) report-
ed that the overproduction of MMP-3 in mam-
mary gland tissue triggered surrounding cells to 
increasingly produce reactive oxygen species, and 
induced DNA injury and genetic instability, fi-
nally leading to malignant conversion.  Colorectal 
cancer may develop via a similar course. 
 While MMP-7 has a broad substrate speci-
ficity, it also exhibits “sheddase” activity mediat-
ing cell surface protein release, and its influence 
on the growth and progression of colorectal, 
esophageal, stomach, and lung cancers has been 
investigated (Leeman et al., 2003; Zhang et al., 
2005).  A strong correlation of MMP-7 with col-
orectal cancer malignancy has been reported, in 
which the expression frequency of MMP-7 was 
particularly high in cancer tissues, and the MMP-
7 expression level was higher in metastatic le-
sions than in the primary lesion (Yoshimoto et al., 
1993).  In the MMP-7 gene, A/G polymorphism 
is present at –181 of the promoter lesion, and the 
transcription activity is higher in the G than in 
the A allele (Ghilardi et al., 2003).  Ghilardi et 
al. (2003) reported that the MMP-7 –181 G/G 
genotype was involved in colorectal cancer and 
tumor progression in Italians, but we detected no 
association of MMP-7 gene polymorphisms with 
colorectal neoplasm susceptibility or tumor pro-
gression.  One reason may have been the biased 
distribution of MMP-7 polymorphisms.  The fre-
quency of MMP-7 G/G was about 0.5% in healthy 
subjects in a study performed in China (Lu et al., 
2006), but about 20% in another Asian country, 
India (Singh et al., 2008), suggesting regional 
variation.  Actually, none of the subjects analyzed 
showed MMP-7 G/G in our study. 
 Regarding MMP-9, Zucker and Varcrca 
(2004) reported that the MMP-9 level rose in an 
early stage after the progression of adenoma to 
colon cancer, and Roeb et al. (2001) reported that 
MMP-9 transcription activity was 5 times higher 
in colorectal cancer than in the normal mucosa. 
In the MMP-9 gene, T/C polymorphism is present 
at –1562, and the transcription activity is higher 
in the C than in the T allele (Zhang et al., 1999). 
Matsumura et al. (2005) reported a relationship 
between stomach cancer invasion and the MMP-9 
T allele position, and Grieu et al. (2004) reported 
that C homo improved the prognosis of breast 
cancer.  Regarding colorectal cancer, Elander et 
al. (2006) investigated the relationship between 
C/T polymorphism at –1562 and colorectal can-
cer, and found no correlation, as observed in our 
study.
 In the TNF-alpha gene, G/A polymorphism 
is present at –308, and the transcription activity 
is higher in the A than in the G allele (Abraham 
and Kroeger, 1999).  Previous reports, however, 
support that there is no significant association be-
tween the TNF-alpha –308 A/G allele and colorec-
tal cancer susceptibility (Park et al., 1998; Landi et 
al., 2003).  The findings of our study are similar to 
those reports.
 The present study clarified that the suscep-
tibility to colorectal cancer is more strongly af-
fected by age, gender, and cigarette-smoking and 
alcohol-drinking histories in Japanese, as reported 
by Otani et al. (2003), than gene polymorphisms 
studied.  Colorectal cancer is a multifactorial dis-
ease involving environmental factors as well as 
a genetic predisposition, and properly cannot be 
explained by genetic predisposition alone.  How-
ever, detailed clarification of the involvement of a 
genetic predisposition may contribute to the pre-
diction and early discovery of cancer development 
as well as elucidation of the molecular mechanism 
involved in the carcinogenic factors and early 
stage of carcinogenesis. 
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 In conclusion, no association with the sus-
ceptibility to colorectal neoplasm was noted in 
any polymorphism of the MMP-2, -3, -7 and -9 
and TNF-alpha genes, but the involvement of the 
MMP-3 5A allele in tumor progression was sug-
gested.  
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